Skip to main content
Erschienen in: International Journal of Bipolar Disorders 1/2014

Open Access 01.12.2014 | Editorial

The impact of treatment decisions on the diagnosis of bipolar disorders

verfasst von: Emanuel Severus, Michael Bauer

Erschienen in: International Journal of Bipolar Disorders | Ausgabe 1/2014

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN

Editorial

The fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) has broadened the criteria for specified bipolar disorders with the introduction of the diagnostic category of ‘other specified bipolar and related disorders’ (DSM-5: 296.89). In a prior editorial, we critically discussed how the way we diagnose bipolar disorders may impact treatment decisions, especially for patients with newly specified subthreshold bipolar II disorder (full depressive episode plus a hypomanic episode that does not meet the duration or number of symptoms required for a full episode) (Frances and Jones 2012; Phillips and Kupfer 2013; Severus and Bauer 2013; Zimmerman 2012; Angst 2013). In this editorial, we will examine how treatment decisions may, in turn, impact the diagnosis of bipolar disorders. Specifically, we will focus on how acute and prophylactic treatment of subthreshold bipolar II disorder may impact the rate of conversion to a diagnosis of bipolar I disorder.
In the DSM-5, subtypes of the nonorganic bipolar disorders are differentiated primarily by the number, duration, and intensity of the manic symptoms, as summarized in Table 1. To illustrate how the treatment of subthreshold bipolar II disorder may impact diagnosis, we will consider the case of a young patient with a history of a major depressive episode who visits his psychiatrist. Starting abruptly over the last 2 days, the patient felt increasingly ‘hyper’ and energetic despite sleeping less than usual and had a fierce argument with his girlfriend. On close scrutiny, it turned out that the patient's history is also positive for a single past episode of short-duration hypomania, but negative for hypomanic or manic episodes, use of antidepressants, other substance use, and medical comorbidities (Do and Mezuk 2013). However, his father suffers from severe bipolar I disorder. The patient is exhibiting a prototype hypomanic syndrome (DeFife et al. 2013), meets the DSM-5 criteria for ‘short-duration hypomanic episodes (2 to 3 days) and major depressive episodes,’ and is therefore diagnosed with ‘other specified bipolar and related disorders.’ From a clinical perspective, the current hypomanic syndrome may be the beginning of a full manic episode, particularly with the positive family history. Now consider the potential impact of three acute treatment approaches on the future diagnosis of this patient: (1) The psychiatrist prescribes a high dose of a fast-acting drug approved for the acute treatment of manic episodes, such as an atypical antipsychotic, with the possibility of further dose escalation. With this medication regimen, the hypomanic syndrome will probably decrease within a short period of time. Two days later, the patient may no longer meet the full criteria for a hypomanic episode and the diagnosis of ‘other specified bipolar and related disorders’ will remain. (2) The psychiatrist prescribes a lower dose of the same atypical antipsychotic. In this case, the patient may still meet the criteria for a hypomanic episode 2 days later and will be diagnosed with bipolar II disorder. (3) The psychiatrist decides on watchful waiting and prescribes only a mild hypnotic. The patient will develop a manic episode and will be diagnosed with bipolar I disorder.
Table 1
Minimum requirements for diagnosis of selected bipolar subtypes in DSM-5
Subtype
At least one full manic episode
At least one full major depressive episode
At least one full hypomanic episode
At least one subthreshold hypomanic episode
Bipolar I disorder
Yes
No
No
No
Bipolar II disorder
No
Yes
Yes
No
Short-duration hypomanic episodes (2 to 3 days) and major depressive episodes (other specified bipolar and related disorders)
No
Yes
No
Yes (2 episodes of short-duration hypomania)
Hypomanic episodes with insufficient symptoms and major depressive episodes (other specified bipolar and related disorders)
No
Yes
No
Yes
Similarly, long-term treatment may impact the diagnosis. Assume the patient in this example develops a hypomanic episode and is diagnosed with bipolar II disorder. Once remission is achieved, given the recent episode and family history of bipolar I disorder, prophylactic antimanic treatment is recommended in recent guidelines (Pfennig et al. 2012). The intensity of this prophylactic treatment (low to moderate dose of an atypical antipsychotic or, if further hypomanic episodes occur, a combination of this atypical antipsychotic and lithium), and the extent to which the patient adheres to this treatment, may largely influence whether this patient will develop a manic episode and subsequently be diagnosed with bipolar I disorder.
Although bipolar I and bipolar II disorders are reported to differ in clinical correlates such as age of onset or course of illness (Angst et al. 2010; Merikangas et al. 2007), these findings may be less valid in the future. With the expansion of the diagnostic criteria, a diagnosis of bipolar I disorder may be more related to treatment decisions for subthreshold bipolar II states rather than to differences in pathophysiology. In this context, the current emphasis on further delineating subtypes of bipolar disorders may be questioned. We suggest there is a need to better differentiate subthreshold hypomanic episodes from similar symptoms that occur in differential diagnoses such as normal mood swings, ADHD, narcissistic personality disorder, or borderline personality disorder (Kernberg and Yeomans 2013; Zimmerman et al. 2013). For example, in a patient presenting with a major depressive episode, probing for past ‘hyper or wired’ states with a discernible beginning and end, and including information provided by significant others, may be of help. In case of doubt, we recommend waiting until the patient has remitted and again experiences a ‘hyper or wired’ state rather than starting treatment for bipolar disorders. At this point, the patient should be reassessed by the psychiatrist and a more definite diagnosis made.
We also suggest there is an immediate need for research to more accurately capture the very essence of prototypic subthreshold hypomanic episodes. This includes prospectively and objectively measuring behavioral variables associated with subthreshold and hypomanic episodes such as communication patterns, speech, or range of motion. Projects should include the use of innovative ambulatory monitoring with wearable technologies or smartphones (Ebner-Priemer and Trull 2009; Trull and Ebner-Priemer 2013; Faurholt-Jepsen et al. 2013), in conjunction with self-ratings, and prospective clinical assessments. Better understanding of the longitudinal course of all bipolar disorder subtypes included in the DSM-5 is needed.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://​creativecommons.​org/​licenses/​by/​4.​0), which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
download
DOWNLOAD
print
DRUCKEN
Literatur
Zurück zum Zitat Angst J, Cui L, Swendsen J, Rothen S, Cravchik A, Kessler RC, Merikangas KR: Major depressive disorder with subthreshold bipolarity in the National Comorbidity Survey Replication. Am J Psychiatry 2010,167(10):1194–1201. 10.1176/appi.ajp.2010.09071011PubMedCentralCrossRefPubMed Angst J, Cui L, Swendsen J, Rothen S, Cravchik A, Kessler RC, Merikangas KR: Major depressive disorder with subthreshold bipolarity in the National Comorbidity Survey Replication. Am J Psychiatry 2010,167(10):1194–1201. 10.1176/appi.ajp.2010.09071011PubMedCentralCrossRefPubMed
Zurück zum Zitat DeFife JA, Peart J, Bradley B, Ressler K, Drill R, Westen D: Validity of prototype diagnosis for mood and anxiety disorders. JAMA Psychiatr 2013,70(2):140–148. 10.1001/jamapsychiatry.2013.270CrossRef DeFife JA, Peart J, Bradley B, Ressler K, Drill R, Westen D: Validity of prototype diagnosis for mood and anxiety disorders. JAMA Psychiatr 2013,70(2):140–148. 10.1001/jamapsychiatry.2013.270CrossRef
Zurück zum Zitat Ebner-Priemer UW, Trull TJ: Ecological momentary assessment of mood disorders and mood dysregulation. Psychol Assess 2009,21(4):463–475.CrossRefPubMed Ebner-Priemer UW, Trull TJ: Ecological momentary assessment of mood disorders and mood dysregulation. Psychol Assess 2009,21(4):463–475.CrossRefPubMed
Zurück zum Zitat Faurholt-Jepsen M, Vinberg M, Christensen EM, Frost M, Bardram J, Kessing LV: Daily electronic self-monitoring of subjective and objective symptoms in bipolar disorder–the MONARCA trial protocol (MONitoring, treAtment and pRediCtion of bipolAr disorder episodes): a randomised controlled single-blind trial. BMJ Open. 2013, 3: 7.CrossRef Faurholt-Jepsen M, Vinberg M, Christensen EM, Frost M, Bardram J, Kessing LV: Daily electronic self-monitoring of subjective and objective symptoms in bipolar disorder–the MONARCA trial protocol (MONitoring, treAtment and pRediCtion of bipolAr disorder episodes): a randomised controlled single-blind trial. BMJ Open. 2013, 3: 7.CrossRef
Zurück zum Zitat Frances A, Jones KD: Bipolar disorder type II revisited. Bipolar Disord 2012,14(5):474–477. 10.1111/j.1399-5618.2012.01038.xCrossRefPubMed Frances A, Jones KD: Bipolar disorder type II revisited. Bipolar Disord 2012,14(5):474–477. 10.1111/j.1399-5618.2012.01038.xCrossRefPubMed
Zurück zum Zitat Kernberg OF, Yeomans FE: Borderline personality disorder, bipolar disorder, depression, attention deficit/hyperactivity disorder, and narcissistic personality disorder: practical differential diagnosis. Bull Menninger Clin 2013,77(1):1–22. 10.1521/bumc.2013.77.1.1CrossRefPubMed Kernberg OF, Yeomans FE: Borderline personality disorder, bipolar disorder, depression, attention deficit/hyperactivity disorder, and narcissistic personality disorder: practical differential diagnosis. Bull Menninger Clin 2013,77(1):1–22. 10.1521/bumc.2013.77.1.1CrossRefPubMed
Zurück zum Zitat Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RM, Petukhova M, Kessler RC: Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 2007,64(5):543–552. 10.1001/archpsyc.64.5.543PubMedCentralCrossRefPubMed Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RM, Petukhova M, Kessler RC: Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 2007,64(5):543–552. 10.1001/archpsyc.64.5.543PubMedCentralCrossRefPubMed
Zurück zum Zitat Pfennig A, Bschor T, Baghai T, Braunig P, Brieger P, Falkai P, Geissler D, Gielen R, Giesler H, Gruber O, Kopp I, Meyer TD, Möhrmann KH, Muche-Borowski C, Padberg F, Scherk H, Strech D, Bauer M: S3 guidelines on diagnostics and therapy of bipolar disorders: development process and essential recommendations. Nervenarzt 2012,83(5):568–586. 10.1007/s00115-011-3415-3CrossRefPubMed Pfennig A, Bschor T, Baghai T, Braunig P, Brieger P, Falkai P, Geissler D, Gielen R, Giesler H, Gruber O, Kopp I, Meyer TD, Möhrmann KH, Muche-Borowski C, Padberg F, Scherk H, Strech D, Bauer M: S3 guidelines on diagnostics and therapy of bipolar disorders: development process and essential recommendations. Nervenarzt 2012,83(5):568–586. 10.1007/s00115-011-3415-3CrossRefPubMed
Zurück zum Zitat Phillips ML, Kupfer DJ: Bipolar disorder diagnosis: challenges and future directions. Lancet 2013,381(9878):1663–1671. 10.1016/S0140-6736(13)60989-7CrossRefPubMed Phillips ML, Kupfer DJ: Bipolar disorder diagnosis: challenges and future directions. Lancet 2013,381(9878):1663–1671. 10.1016/S0140-6736(13)60989-7CrossRefPubMed
Zurück zum Zitat Zimmerman M: Would broadening the diagnostic criteria for bipolar disorder do more harm than good? Implications from longitudinal studies of subthreshold conditions. J Clin Psychiatry 2012,73(4):437–443. 10.4088/JCP.11com07288CrossRefPubMed Zimmerman M: Would broadening the diagnostic criteria for bipolar disorder do more harm than good? Implications from longitudinal studies of subthreshold conditions. J Clin Psychiatry 2012,73(4):437–443. 10.4088/JCP.11com07288CrossRefPubMed
Zurück zum Zitat Zimmerman M, Martinez JH, Morgan TA, Young D, Chelminski I, Dalrymple K: Distinguishing bipolar II depression from major depressive disorder with comorbid borderline personality disorder: demographic, clinical, and family history differences. J Clin Psychiatry 2013,74(9):880–886. 10.4088/JCP.13m08428CrossRefPubMed Zimmerman M, Martinez JH, Morgan TA, Young D, Chelminski I, Dalrymple K: Distinguishing bipolar II depression from major depressive disorder with comorbid borderline personality disorder: demographic, clinical, and family history differences. J Clin Psychiatry 2013,74(9):880–886. 10.4088/JCP.13m08428CrossRefPubMed
Metadaten
Titel
The impact of treatment decisions on the diagnosis of bipolar disorders
verfasst von
Emanuel Severus
Michael Bauer
Publikationsdatum
01.12.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
International Journal of Bipolar Disorders / Ausgabe 1/2014
Elektronische ISSN: 2194-7511
DOI
https://doi.org/10.1186/2194-7511-2-3

Weitere Artikel der Ausgabe 1/2014

International Journal of Bipolar Disorders 1/2014 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.